Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

Patients with salivary duct cancer (SDC) and HER2 overexpression could receive trastuzumab in combination with chemotherapy for metastatic disease. No standard treatment exists for patients with HER2-positive metastatic SDC after progression. We report an excellent patient response to second-line tr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Case Rep Oncol
Hlavní autoři: Corrêa, Tatiana Strava, Matos, Gustavo Duarte Ramos, Segura, Marcos, dos Anjos, Carlos Henrique
Médium: Artigo
Jazyk:Inglês
Vydáno: S. Karger AG 2018
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5981674/
https://ncbi.nlm.nih.gov/pubmed/29867432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000488669
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky